Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
2019 ◽
Vol 85
(8)
◽
pp. 1808-1819
◽
2015 ◽
Vol 37
(1)
◽
pp. 71-82.e12
◽
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
2019 ◽
Vol 19
(20)
◽
pp. 1818-1849
◽
2021 ◽
Vol 12
◽
pp. 204201882110002
2018 ◽
Vol 39
(2)
◽
pp. 179-186
◽
2017 ◽
Vol 18
(1)
◽
pp. 108-114
◽
2017 ◽
Vol 37
(1)
◽
pp. 9-17
◽
Keyword(s):
2020 ◽
Vol 92
(5)
◽
pp. 110-118
◽